MVM has invested in high growth healthcare businesses since 1997. With teams in Boston and London, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare.

$

1

B

Assets managed

>

100


Collective years investing in healthcare

34


Exits

1997


Founded

Working with MVM

MVM partners with best-in-class management teams to bring innovative products to market, drive growth, make strategic acquisitions, and establish new standards of care in medicine.

We seek out portfolio companies that address significant unmet needs in large addressable markets. These include medical conditions for which there is no adequate treatment, therapies for which existing technologies are too expensive, or diseases for which there is no accurate diagnostic capability, among other situations.

In all of these cases, we prioritize businesses that have a clearly differentiated technology with durable protection against competition, whether through intellectual property, barriers to market entry, statutory exclusivity, or unique branding. After investment, we work closely with management teams to help the business achieve both its near and long term goals.

Work section image

Investment Approach

While MVM does not use fixed investment criteria, we focus on companies that fit the following profile.

Stage

We provide growth equity to commercial-stage businesses. In other words, our investments are intended to accelerate the growth and scale of companies that have commercially available products.

Sector

We invest broadly across healthcare and life sciences. We have made investments in medical devices, pharmaceuticals, diagnostics, digital health, health IT, life science tools, contract research, and contract manufacturing, among other areas. We focus on identifying differentiated products or technologies in each of these categories.

Size

We expect to make aggregate investments of $10 to 50 million in each of our portfolio companies over the life of our holding. In select circumstances, we have the capacity to make larger investments to support unique or creative financing opportunities.

Building image
Door image

Portfolio

MVM invests in innovative healthcare companies. Our active portfolio companies are transforming the delivery of healthcare by enabling higher quality, cost-effective care in large, global markets. We maintain a concentrated portfolio, focused on building world-class companies.

Exits

MVM has extensive experience guiding our portfolio companies to successful exits, including both acquisitions and initial public offerings. Selected former portfolio companies include:

City image

Latest news

Vertos mild® Patients Demonstrate Durable 5 Year Outcomes
May 18, 2021

Most Minimally Invasive Lumbar Decompression (mild®) providers are very familiar with the 1-year study conducted by Nagy Mekhail, MD, PhD […]

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
May 11, 2021

Saint-Herblain (France), May 6, 2021  – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for […]

Valneva Initiates Phase 3 Clinical Trial for its Inactivated,
Adjuvanted COVID-19 Vaccine Candidate, VLA2001
April 29, 2021

Saint-Herblain (France), April 21, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic […]

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
April 6, 2021

April 6, 2021 VLA2001 was well tolerated with no safety concerns identified In the high dose group : IgG seroconversion […]

eXmoor pharma secures £12m ($17m) from healthcare investment firm MVM marking milestone towards significant expansion plans
March 16, 2021

eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) […]

Hologic announces acquisition of Biotheranostics
January 5, 2021

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has agreed to acquire Biotheranostics, Inc., […]

MVM invests in GT Medical
November 23, 2020

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has […]

Valneva announces major COVID-19 vaccine partnership with UK government
September 14, 2020

– UK Government has secured supply of 60 million doses at a cost of €470 million with options over another […]

MVM invests in Paragon 28
August 15, 2020

Paragon 28, Inc., a leading orthopedic foot and ankle company, today announced the completion of a Series B financing. The […]

Valneva confirms participation in UK government COVID-19 vaccine response program
July 20, 2020

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today confirmed its participation in […]

Contact Us

info@mvm.com

MVM Partners

Old City Hall, 45 School Street

Boston MA 02108

MVM Partners

30 St George Street

London W1S 2FH